The assay detects the overexpression of c-Met found in more than half of individuals with advanced non-small cell lung cancer. Credit: JOURNEY STUDIO7 / Shutterstock.

NeoGenomics has commercially launched the c-MET Companion Diagnostic (CDx) for use in non-small cell lung cancer (NSCLC), offering a 48-hour turnaround for oncologists and pathologists.

This new immunohistochemistry (IHC) assay is designed to detect the overexpression of c-Met (mesenchymal-epithelial transition factor) protein, which is found in up to half of individuals with advanced NSCLC.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The c-MET CDx for NSCLC assay is intended to detect individuals who may benefit from targeted therapies such as AbbVie’s Emrelis (telisotuzumab vedotin-tllv), which was recently approved by the US Food and Drug Administration (FDA).

Developed in line with the regulator’s guidance, the assay is said to be validated for use with MET-targeted treatments while enabling timely clinical decision-making.

NeoGenomics noted that the assay complements the company’s PanTracer portfolio, which includes genomic and immuno-oncology markers.

It forms part of the company’s extensive NSCLC testing offerings, supporting the adoption of MET-directed treatments and the advancement of precision cancer care.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Headquartered in the US, NeoGenomics focuses on cancer genetics testing and information services and provides a range of oncology-focused tests.

NeoGenomics medical services vice-president Dr Nathan Montgomery said: “Accurate and timely biomarker testing is critical in lung cancer, where targeted therapies can meaningfully change the course of a patient’s treatment.

“The c-MET CDx for NSCLC assay adds an important tool to our testing portfolio, helping oncologists quickly identify patients who may benefit from MET-directed therapies. It also complements our PanTracer suite, enabling comprehensive biomarker profiling for NSCLC.”

In October 2024, the company announced the receipt of conditional approval from the New York State Department of Health for two next-generation sequencing (NGS) tests, the Neo Comprehensive Solid Tumor assay and the NeoTYPE DNA & RNA Lung.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now